Hims & Hers Health Stock Surges 16% on Women’s Health Expansion
Hims & Hers Health (HIMS) shares jumped 16% following the company's announcement of expanded treatment options for perimenopause and menopause. The women's division now boasts over 500,000 subscribers and is projected to exceed $1 billion in annual revenue by 2026.
Bank of America analyst Allen Lutz highlighted the MOVE as a strategic entry into a multi-billion-dollar market. Technical indicators reinforce optimism—the stock's MACD signals a Buy, while its current price of $62.76 sits well above the 50-day EMA of $52.99.
Momentum metrics like the Rate of Change further support bullish sentiment, suggesting potential upside despite today's sharp rally.